Ilyang’s new leukemia drug shows promise

Published: 2011-08-16 06:57:00
Updated: 2011-08-16 06:57:00
Ilyang Pharmaceutical Co. says it will carry out a Phase III clinical trial of radotinib, a new leukemia medicine.

The drug is believed to be 30 times more effective than Gleevec, a popular anti-leukemia medicine.

If successful, it is expected to change the landscape of the leukemia drug m...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.